Zevra Therapeutics Chief Medical Officer Resigns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Zevra Therapeutics announced that its chief medical officer, Adrian Quartel, will step down from his position due to personal reasons, effective July 3. Quartel will continue to support the company in a consulting capacity through December 31, while Zevra conducts a search for its next medical chief. The company noted that its upcoming regulatory milestones, including the European review of arimoclomol for Niemann-Pick disease, remain on track.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.970
Low
21.00
Averages
24.00
High
26.00
Current: 13.970
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Publishes Encouraging Phase 2/3 Data for MIPLYFFA in Niemann-Pick Disease
- Clinical Trial Results: Zevra Therapeutics announced encouraging Phase 2/3 data for MIPLYFFA in treating Niemann-Pick type C disease in pediatric patients under two years old, indicating good safety and potential therapeutic effects, which may offer new hope for patients with this rare disease.
- Drug Mechanism: MIPLYFFA (arimoclomol) activates E3 and EB transcription factors to upregulate CLEAR genes, facilitating the removal of unesterified cholesterols from fibroblast lysosomes, thereby halting disease progression and highlighting its significance in treating metabolic disorders.
- Regulatory Progress: Zevra has filed a Marketing Authorization Application (MAA) with the European Medicines Agency to clear arimoclomol as a treatment for Niemann-Pick disease, and approval would further enhance the company's market position in the rare disease sector.
- Market Reaction: ZVRA's stock closed up 2.77% at $13 on Tuesday, although it dipped 0.54% to $12.93 in after-hours trading, reflecting a positive investor response to the clinical data while maintaining cautious sentiment regarding future regulatory outcomes.
See More
Zevra Publishes Arimoclomol Study Results in Infants
- Clinical Study Results: Zevra Therapeutics announced the publication of results from a phase 2/3 open-label study evaluating arimoclomol in infants aged 12 to 24 months with Niemann-Pick disease type C, demonstrating good safety and tolerability while pharmacokinetic results align with older pediatric populations, indicating potential for earlier treatment initiation.
- Drug Approval Background: Arimoclomol was approved by the FDA in September 2024 for the treatment of Niemann-Pick disease type C, showing its ability to enhance the activation of transcription factors EB and E3, leading to the upregulation of CLEAR genes, which suggests long-term clinical benefits for patients.
- Market Potential: Zevra's MIPLYFFA has been tested in over 270 patients globally, providing more than five years of patient experience, showcasing the drug's broad applicability in treating Niemann-Pick disease type C, particularly in pediatric patients.
- Regulatory Application Progress: Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for arimoclomol, aiming to expand its market share in the treatment of Niemann-Pick disease type C, reflecting the company's ongoing investment and commitment to this field.
See More
Zevra Therapeutics Price Target Raised to $25 Amid Positive Analyst Sentiment
- Analyst Price Target Increase: Citizens raised Zevra Therapeutics' price target from $18 to $25 while maintaining an 'Outperform' rating, reflecting optimism regarding the extended market exclusivity of Miplyffa, which is expected to further boost investor confidence.
- Strong Market Performance: Shares of Zevra Therapeutics jumped 8% on Tuesday, reaching their highest level in nearly five years, as investors reacted strongly to favorable analyst commentary linked to recent patent developments, indicating enhanced market confidence in the company's long-term prospects.
- Miplyffa Sales Surge: In 2025, Miplyffa generated $87.4 million in revenue, accounting for over 80% of Zevra's total sales, marking a significant increase from $10.1 million the previous year, underscoring the drug's importance and market demand in treating rare neurological disorders.
- Investor Sentiment Shift: Retail sentiment surrounding ZVRA on Stocktwits shifted from 'neutral' to 'extremely bullish,' with message volumes surging nearly 1,200% over the past 24 hours, reflecting strong optimism about the stock's future performance.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Zevra's Patent Protection Extended to 2041 for MIPLYFFA
- Enhanced Patent Protection: Zevra Therapeutics announced that the new patent for its only FDA-approved drug, MIPLYFFA, will protect its market position until 2041, blocking cheaper generic alternatives and significantly boosting investor confidence while ensuring stable future cash flows.
- Significant Revenue Growth: In 2025, MIPLYFFA generated $87.4 million in net revenue, a substantial increase from $10.1 million in 2024, accounting for 82% of the company's total net revenue, indicating that the drug's strong market performance has propelled Zevra from a net loss to profitability.
- Analyst Outlook Positive: Cantor Fitzgerald analyst Kristen Kluska raised Zevra's price target from $24 to $34 while maintaining an 'Overweight' rating, citing the new patent's
See More
Zevra Submits MIPLYFFA Patent for Orange Book Listing
- Enhanced Patent Protection: Zevra Therapeutics has submitted a patent application for MIPLYFFA® (arimoclomol) with a validity extending to 2041, further strengthening its intellectual property protection and ensuring competitive advantage in the future market.
- Addressing Unmet Needs: MIPLYFFA represents a crucial therapeutic option for patients with Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease, highlighting the company's commitment to addressing patient needs.
- Market Access Strategy: By listing the patent in the FDA's Orange Book, Zevra aims to clarify the market exclusivity of its branded drug, thereby delaying the entry of generic competitors, protecting its market share, and enhancing long-term value.
- Patent Term Extension Application: The company has also applied for an extension of another patent set to expire in 2029, currently awaiting a determination from the U.S. Patent and Trademark Office, demonstrating its proactive strategy in intellectual property management.
See More
Zevra Publishes Encouraging Phase 2/3 Data for MIPLYFFA in Niemann-Pick Disease
- Clinical Trial Results: Zevra Therapeutics announced encouraging Phase 2/3 data for MIPLYFFA in treating Niemann-Pick type C disease in pediatric patients under two years old, indicating good safety and potential therapeutic effects, which may offer new hope for patients with this rare disease.
- Drug Mechanism: MIPLYFFA (arimoclomol) activates E3 and EB transcription factors to upregulate CLEAR genes, facilitating the removal of unesterified cholesterols from fibroblast lysosomes, thereby halting disease progression and highlighting its significance in treating metabolic disorders.
- Regulatory Progress: Zevra has filed a Marketing Authorization Application (MAA) with the European Medicines Agency to clear arimoclomol as a treatment for Niemann-Pick disease, and approval would further enhance the company's market position in the rare disease sector.
- Market Reaction: ZVRA's stock closed up 2.77% at $13 on Tuesday, although it dipped 0.54% to $12.93 in after-hours trading, reflecting a positive investor response to the clinical data while maintaining cautious sentiment regarding future regulatory outcomes.
See More
Zevra Publishes Arimoclomol Study Results in Infants
- Clinical Study Results: Zevra Therapeutics announced the publication of results from a phase 2/3 open-label study evaluating arimoclomol in infants aged 12 to 24 months with Niemann-Pick disease type C, demonstrating good safety and tolerability while pharmacokinetic results align with older pediatric populations, indicating potential for earlier treatment initiation.
- Drug Approval Background: Arimoclomol was approved by the FDA in September 2024 for the treatment of Niemann-Pick disease type C, showing its ability to enhance the activation of transcription factors EB and E3, leading to the upregulation of CLEAR genes, which suggests long-term clinical benefits for patients.
- Market Potential: Zevra's MIPLYFFA has been tested in over 270 patients globally, providing more than five years of patient experience, showcasing the drug's broad applicability in treating Niemann-Pick disease type C, particularly in pediatric patients.
- Regulatory Application Progress: Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for arimoclomol, aiming to expand its market share in the treatment of Niemann-Pick disease type C, reflecting the company's ongoing investment and commitment to this field.
See More
Zevra Therapeutics Price Target Raised to $25 Amid Positive Analyst Sentiment
- Analyst Price Target Increase: Citizens raised Zevra Therapeutics' price target from $18 to $25 while maintaining an 'Outperform' rating, reflecting optimism regarding the extended market exclusivity of Miplyffa, which is expected to further boost investor confidence.
- Strong Market Performance: Shares of Zevra Therapeutics jumped 8% on Tuesday, reaching their highest level in nearly five years, as investors reacted strongly to favorable analyst commentary linked to recent patent developments, indicating enhanced market confidence in the company's long-term prospects.
- Miplyffa Sales Surge: In 2025, Miplyffa generated $87.4 million in revenue, accounting for over 80% of Zevra's total sales, marking a significant increase from $10.1 million the previous year, underscoring the drug's importance and market demand in treating rare neurological disorders.
- Investor Sentiment Shift: Retail sentiment surrounding ZVRA on Stocktwits shifted from 'neutral' to 'extremely bullish,' with message volumes surging nearly 1,200% over the past 24 hours, reflecting strong optimism about the stock's future performance.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Zevra's Patent Protection Extended to 2041 for MIPLYFFA
- Enhanced Patent Protection: Zevra Therapeutics announced that the new patent for its only FDA-approved drug, MIPLYFFA, will protect its market position until 2041, blocking cheaper generic alternatives and significantly boosting investor confidence while ensuring stable future cash flows.
- Significant Revenue Growth: In 2025, MIPLYFFA generated $87.4 million in net revenue, a substantial increase from $10.1 million in 2024, accounting for 82% of the company's total net revenue, indicating that the drug's strong market performance has propelled Zevra from a net loss to profitability.
- Analyst Outlook Positive: Cantor Fitzgerald analyst Kristen Kluska raised Zevra's price target from $24 to $34 while maintaining an 'Overweight' rating, citing the new patent's
See More
Zevra Submits MIPLYFFA Patent for Orange Book Listing
- Enhanced Patent Protection: Zevra Therapeutics has submitted a patent application for MIPLYFFA® (arimoclomol) with a validity extending to 2041, further strengthening its intellectual property protection and ensuring competitive advantage in the future market.
- Addressing Unmet Needs: MIPLYFFA represents a crucial therapeutic option for patients with Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease, highlighting the company's commitment to addressing patient needs.
- Market Access Strategy: By listing the patent in the FDA's Orange Book, Zevra aims to clarify the market exclusivity of its branded drug, thereby delaying the entry of generic competitors, protecting its market share, and enhancing long-term value.
- Patent Term Extension Application: The company has also applied for an extension of another patent set to expire in 2029, currently awaiting a determination from the U.S. Patent and Trademark Office, demonstrating its proactive strategy in intellectual property management.
See More
